Literature DB >> 24448782

Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit.

Xinghua Liu1, Zhihong Wang2, Yiyuan Xia1, Guang Yu1, Kuan Zeng1, Hongbin Luo1, Jichang Hu1, Cheng-Xin Gong3, Jian-Zhi Wang1, Xin-Wen Zhou1, Xiao-Chuan Wang1.   

Abstract

Recent studies have reported a correlation between dementia and low blood pressure. How hypotension is associated with the increased risk of Alzheimer's disease (AD) remains unclear. Here we show that one month treatment of losartan, an angiotensin II type 1 (AT1) receptor antagonist, causes chronic and sustained hypotension, along with oxidative stress in adult male Sprague-Dawley rats. Furthermore, we show that losartan treatment increases the level of inactivated protein phosphatase 2A (PP2A) and the hyperphosphorylation of tau at Ser 199 and Ser 396. Rats treated with losartan present memory deficits and decreases in spine-density. These findings suggest that losartan-induced hypotension may increase the risk of AD-like pathological alteration and behavioral impairment through oxidative stress which leads to tau hyperphosphorylation and loss of dendritic spines.

Entities:  

Keywords:  Alzheimer's disease; hypotension; losartan; memory deficit; oxidative stress; tau hyperphosphorylation

Mesh:

Substances:

Year:  2014        PMID: 24448782     DOI: 10.3233/JAD-131679

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  3 in total

Review 1.  Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease.

Authors:  Rong-Hong Ma; Yao Zhang; Xiao-Yue Hong; Jun-Fei Zhang; Jian-Zhi Wang; Gong-Ping Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

2.  The Emerging Evidence for a Protective Role of Fucoidan from Laminaria japonica in Chronic Kidney Disease-Triggered Cognitive Dysfunction.

Authors:  Zhihui Ma; Zhiyou Yang; Xinyue Feng; Jiahang Deng; Chuantong He; Rui Li; Yuntao Zhao; Yuewei Ge; Yongping Zhang; Cai Song; Saiyi Zhong
Journal:  Mar Drugs       Date:  2022-04-07       Impact factor: 6.085

Review 3.  Drug repositioning and repurposing for Alzheimer disease.

Authors:  Clive Ballard; Dag Aarsland; Jeffrey Cummings; John O'Brien; Roger Mills; Jose Luis Molinuevo; Tormod Fladby; Gareth Williams; Pat Doherty; Anne Corbett; Janet Sultana
Journal:  Nat Rev Neurol       Date:  2020-09-16       Impact factor: 42.937

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.